Neogen (NEOG) Q2 2026: EBITDA Margin Jumps 470bps as Cost Actions Take Hold
Neogen’s transformation is gaining traction, as sequential EBITDA margin expansion and a return to core growth signal early success from operational resets and leadership overhaul. Margin improvement is being driven by cost reductions and improved execution, while the company maintains a cautious outlook amid lingering macro headwinds and ongoing segment integration. Investors should watch for further gains in operational discipline and the outcome of the genomics divestiture as Neogen positions for its next phase of growth.
Summary
- Margin Expansion: Cost actions and operational discipline drove a sharp improvement in profitability.
- Leadership Overhaul: New executives are accelerating commercial and operational resets.
- Transformation Progress: Early results support raised guidance, but management remains conservative on outlook.
Performance Analysis
Neogen delivered a sequential EBITDA margin improvement of 470 basis points, driven by cost structure changes and a renewed focus on operational execution. Core revenue growth returned across both food safety and animal safety segments for the first time in a year, with food safety leading at over 4% core growth and animal safety flat. The food safety segment, which now constitutes nearly three-quarters of total revenue, benefited from targeted efforts in sample collection and Petri film, both showing notable rebounds. Animal safety saw mixed results, with insect control products gaining share but veterinary instruments and life sciences products lagging due to order timing and market trends.
Gross margin rebounded to 47.5%, up 210 basis points sequentially, with further upside when excluding restructuring costs. Sample collection, previously a drag on margins, showed improvement and is expected to contribute positively in the second half, reflecting operational gains and pricing adjustments. Free cash flow swung positive, aided by lower CapEx and working capital efficiency. Regional performance was led by Latin America and North America, with EMEA and APAC producing mixed results due to product-specific and market factors.
- Food Safety Drives Growth: Indicator testing, culture media, and pathogen detection led segment gains, offsetting softness elsewhere.
- Operational Leverage Emerging: Headcount reductions and inventory focus are translating to higher margins and cash flow.
- Macro Remains Challenging: Food production volumes and animal herds remain at cyclical lows, keeping management cautious.
With core growth and profitability both inflecting, Neogen’s early transformation gains are material but still nascent, with the full impact of leadership changes and process improvements expected to unfold over coming quarters.
Executive Commentary
"Our second quarter performance represents encouraging early progress, with a return to positive core growth across the enterprise and adjusted EBITDA margins, improving nearly 500 basis points sequentially. The initial phase of our transformation is centered on stabilizing and strengthening our core, providing a solid framework for future innovation."
Mike Nessa, Chief Executive Officer
"We saw a return to positive core growth in both segments for the first time in four quarters... Adjusted EBITDA was $48.7 million in the quarter, representing a margin of 21.7%, an improvement of 470 basis points from the first quarter. The margin improvement was driven primarily by the higher gross margin and the headcount reduction implemented during the second quarter."
Brian Rigby, Chief Financial Officer
Strategic Positioning
1. Commercial Excellence and Customer Focus
The shift to a process-driven, customer-centric commercial model is yielding results. Neogen instituted weekly sales forecasting and accountability sessions, replacing a historically less disciplined approach. This has driven better predictability and more accurate guidance, alongside increased cross-portfolio selling to food safety customers—over 75% now purchase multiple categories, with initiatives to push this higher. The commercial reset is being reinforced by new leadership hires with deep diagnostics and operational experience.
2. Operational Efficiency and Cost Discipline
Cost structure improvements are foundational to margin gains. The company implemented actions expected to yield $20 million in annualized savings, including headcount reductions and a renewed focus on inventory management. Sample collection, a gateway product for broader portfolio attachment, is being optimized for profitability, with sequential improvement and a target to return to positive contribution in the back half of the year.
3. Portfolio Simplification and Capital Allocation
Neogen is actively reshaping its business mix for focus and margin. The sale of the cleaners and disinfectants business enabled $100 million in debt paydown, and the genomics business is now in the process of being divested, with proceeds earmarked for further deleveraging. These moves are expected to simplify operations and enhance incremental margins, positioning the company for a more focused growth trajectory.
4. Product Innovation and Integration Projects
The Petri film manufacturing transfer is a critical milestone. Production testing is in late stages, and initial validation has begun, with full process completion targeted by fiscal 2027. Early results are positive, and leadership is not sparing resources on this priority, as successful execution is essential for long-term competitiveness and margin structure in the food safety product line.
Key Considerations
Neogen’s second quarter marks a turning point, but the transformation remains in early innings, with execution risk and macro uncertainty still present. The company’s ability to scale operational discipline and deliver on innovation will determine the sustainability of recent gains.
Key Considerations:
- Execution of Commercial Reset: Weekly forecasting and focused sales enablement are improving predictability, but the new team is still ramping.
- Sample Collection Margin Recovery: Progress is clear, but full normalization and positive profit contribution are still a work in progress.
- Genomics Divestiture Impact: Closing and redeploying proceeds to reduce leverage will clarify the company’s go-forward margin and capital structure.
- Petri Film Manufacturing Transfer: Successful execution is crucial for both cost and supply chain resilience.
- End Market Volatility: Food and animal safety markets remain pressured by production declines and inflation, limiting near-term upside.
Risks
Macroeconomic headwinds, including weak food production volumes and animal herd declines, continue to suppress demand in core markets, while integration and operational execution risks remain as the new leadership team implements wide-ranging changes. Tariff volatility and inventory normalization could also impact margins. The company’s conservative outlook reflects both lingering market uncertainty and the early stage of its transformation.
Forward Outlook
For Q3 2026, Neogen guided to:
- Revenue step-down from Q2 due to seasonality, with Q4 expected to be modestly higher than Q3
- Adjusted EBITDA margins to follow a similar seasonal trend
For full-year 2026, management raised guidance:
- Revenue of $845 million to $855 million
- Adjusted EBITDA of approximately $175 million
Management highlighted several factors that shape the outlook:
- New leadership is still settling in, driving a conservative approach to guidance
- Genomics divestiture is expected to close by fiscal Q4, with proceeds prioritized for debt reduction
Takeaways
Neogen’s margin expansion and return to growth signal early success from operational resets, but execution and macro risks remain as the company transitions to a leaner, more focused model.
- Margin Inflection: Sequential EBITDA margin gains and improving gross margin signal the impact of cost actions and operational discipline.
- Leadership Impact: New executive hires are accelerating commercial and operational changes, but the full benefit will take time to materialize.
- Watch for Divestiture and Integration: The genomics sale and Petri film transfer will be key milestones for margin, focus, and capital allocation in coming quarters.
Conclusion
Neogen’s Q2 results mark a credible inflection in both growth and profitability, driven by disciplined execution and a strengthened leadership team. While early progress is clear, sustained improvement will hinge on continued operational focus, segment integration, and navigating persistent end market volatility.
Industry Read-Through
Neogen’s quarter highlights the importance of operational discipline and commercial focus in the diagnostics and food safety sector, especially as macro headwinds persist. The company’s ability to drive margin expansion through cost actions and portfolio simplification offers a template for peers facing similar end market challenges. Food safety and animal diagnostics players should note the value of customer-centric selling, process discipline, and proactive portfolio management as competitive levers in a slow-growth environment. The Petri film manufacturing transfer and genomics divestiture signal that vertical integration and portfolio focus are likely to be industry-wide themes as companies seek to optimize margin and resilience.